Prevalence and Risk Factors of Osteopenia/osteoporosis in Turkish HIV/AIDS Patients

Overview

Journal Braz J Infect Dis

Specialty Infectious Diseases

Date 2013 Oct 1

PMID 24076108

Citations 14

Authors

Ozlem Altuntas Aydin

Hayat Kumbasar Karaosmanoglu

Ridvan Karahasanoglu

Meryem Tahmaz

Ozcan Nazlican

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies showed a high frequency of low bone mineral density (BMD) in HIV-infected patients and no reports have been issued in Turkey. Our aim was to evaluate BMD and risk factors for osteopenia/osteoporosis in HIV-infected patients that attended an outpatient clinic in Istanbul, Turkey.

Method: In order to determine the prevalence of BMD, 126 HIV-infected patients had been studied with dual energy X-ray absorptiometry (DEXA). The association between BMD and age, gender, body mass index (BMI), habits, 25(OH)vitamin D, HIV RNA, CD4 lymphocyte nadir, using and duration of highly active antiretroviral treatment (HAART) were investigated by using multivariate analysis.

Results: Median age was 40.1 years (range, 20-70); 84% were male; 35.7% patients had AIDS, 63.5% were treated with HAART. Osteopenia and osteoporosis were diagnosed in 53.9% and 23.8%, respectively. Mean plasma HIV RNA was 5.2 (SD 1.0) log10 copies/mL and CD4 lymphocyte nadir was 313.8 (SD 226.2)/mm(3). Factors associated with bone loss were high viral load (p=0.034), using (p=0.033) and duration of HAART (p=0.008). No correlation had been seen between sex and osteopenia/osteoporosis (p=0.794). However, males showed higher rates of osteoporosis than females (p=0.042).

Conclusions: Our results show a very high prevalence of bone mass reduction in Turkish HIV-infected patients. This study supports the importance of both HIV and antiretroviral therapy in low BMD.

Citing Articles

Risk Factors Associated with Osteopenia/Osteoporosis in Antiretroviral Therapy Naive HIV Patients.

Onguru P, Kaya B Curr HIV Res. 2024; 22(4):259-265.

PMID: 38899524 DOI: 10.2174/011570162X311238240603042806.

Bone Metabolism in Men who Live with HIV Aged 50 years and Over: Impact of Infection Duration.

Caglar B, Durcan E, Karaali R, Balkan I, Kaya S, Yavuzer H Curr HIV Res. 2024; 22(1):65-71.

PMID: 38279729 DOI: 10.2174/011570162X273667231213061301.

Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review.

Gusmao M, Oliveira V, Santos N, Melo L Rev Paul Pediatr. 2023; 42:e2023042.

PMID: 37971172 PMC: 10637732. DOI: 10.1590/1984-0462/2024/42/2023042.

The evaluation of risk factors related to reduced bone mineral density in young people living with HIV.

Aydin O, Ankarali H, Ergen P, Baysal N, Cag Y Afr Health Sci. 2023; 22(4):461-469.

PMID: 37092088 PMC: 10117499. DOI: 10.4314/ahs.v22i4.52.

The effect of anti-retroviral therapy on fracture healing : an in vivo animal model.

Graham S, Jalal M, Lalloo D, Simpson A Bone Joint Res. 2022; 11(8):585-593.

PMID: 35942801 PMC: 9396923. DOI: 10.1302/2046-3758.118.BJR-2021-0523.R2.

References

Lawal A, Engelson E, Wang J, Heymsfield S, Kotler D . Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS. 2001; 15(2):278-80. DOI: 10.1097/00002030-200101260-00022. View

Triant V, Brown T, Lee H, Grinspoon S . Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008; 93(9):3499-504. PMC: 2567857. DOI: 10.1210/jc.2008-0828. View

Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A . Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2007; 19(7):913-8. DOI: 10.1007/s00198-007-0524-8. View

Brown T, Qaqish R . Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165-74. DOI: 10.1097/QAD.0b013e32801022eb. View

Fakruddin J, Laurence J . HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003; 278(48):48251-8. DOI: 10.1074/jbc.M304676200. View

Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A . Osteopenia in HIV-infected patients: is it the disease or is it the treatment?. AIDS. 2001; 15(6):807-8. DOI: 10.1097/00002030-200104130-00022. View

Lake J, Adams J . Vitamin D in HIV-Infected Patients. Curr HIV/AIDS Rep. 2011; 8(3):133-41. PMC: 3666828. DOI: 10.1007/s11904-011-0082-8. View

Brainsky A, GLICK H, Lydick E, Epstein R, Fox K, Hawkes W . The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc. 1997; 45(3):281-7. DOI: 10.1111/j.1532-5415.1997.tb00941.x. View

Cozzolino M, Vidal M, Arcidiacono M, Tebas P, Yarasheski K, Dusso A . HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003; 17(4):513-20. DOI: 10.1097/00002030-200303070-00006. View

10.

Pinto Neto L, Ragi-Eis S, Vieira N, Soprani M, Neves M, Ribeiro-Rodrigues R . Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. J Clin Densitom. 2011; 14(4):434-9. DOI: 10.1016/j.jocd.2011.06.004. View

11.

Arnsten J, Freeman R, Howard A, Floris-Moore M, Lo Y, Klein R . Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007; 21(5):617-23. PMC: 2426821. DOI: 10.1097/QAD.0b013e3280148c05. View

12.

Fabbriciani G, De Socio G . Efavirenz and bone health. AIDS. 2009; 23(9):1181. DOI: 10.1097/QAD.0b013e32832bab0f. View

13.

Brown T, Ruppe M, Kassner R, Kumar P, Kehoe T, Dobs A . Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004; 89(3):1200-6. DOI: 10.1210/jc.2003-031506. View

14.

Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, Del Rio L . High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010; 24(18):2827-33. DOI: 10.1097/QAD.0b013e328340a28d. View

15.

Ellfolk M, Norlin M, Gyllensten K, Wikvall K . Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009; 75(6):1392-9. DOI: 10.1124/mol.108.053660. View

16.

Brown T, McComsey G, King M, Qaqish R, Bernstein B, da Silva B . Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009; 51(5):554-61. DOI: 10.1097/QAI.0b013e3181adce44. View

17.

Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N . Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008; 22(3):395-402. DOI: 10.1097/QAD.0b013e3282f423dd. View

18.

Rodriguez M, Daniels B, Gunawardene S, Robbins G . High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2008; 25(1):9-14. DOI: 10.1089/aid.2008.0183. View